Two Seas (NASDAQ: ABUS) reports 18.56M Arbutus shares; 9.4% stake
Two Seas Capital LP, Two Seas Capital GP LLC, and Sina Toussi have reported a beneficial ownership of 18,557,543 common shares, representing a 9.4% stake in Arbutus Biopharma Corporation (NASDAQ: ABUS). This stake is held through two funds: Two Seas Global (Master) Fund LP and Two Seas LNP Opportunities (Master) Fund LP. The reporting persons have sole voting and dispositive power over these shares, calculated based on 196,947,757 common shares outstanding as of March 31, 2026.
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
Arbutus Biopharma Corporation reported strong first-quarter 2026 financial results, including $179.1 million in total revenue, primarily from a litigation settlement with Moderna. The company also announced that its investigational drug, imdusiran, received Fast Track designation from the FDA for chronic hepatitis B, indicating its potential to address an unmet medical need and accelerate development. Arbutus ended the quarter with a strong financial position, holding $95.2 million in cash, cash equivalents, and marketable securities.
Arbutus Biopharma Corp reports results for the quarter ended March 31 - Earnings Summary
Arbutus Biopharma Corp (ABUS) has reported its financial results for the quarter ended March 31. This earnings summary provides a brief overview of the company's performance during the specified period.
Arbutus Biopharma (ABUS) Reports Strong Q1 Earnings with $0.87 EPS
Arbutus Biopharma (ABUS) reported strong Q1 earnings with a GAAP EPS of $0.87 and revenue of $179.1 million, significantly boosted by a litigation settlement with Moderna. The FDA also granted fast track status to its lead asset, enhancing growth prospects. Despite a strong financial position, the company faces challenges in profitability, and its current stock trading near its 52-week high suggests investors are optimistic about future growth.
Arbutus Biopharma earnings beat by $0.91, revenue topped estimates
Arbutus Biopharma (NASDAQ: ABUS) exceeded analyst expectations for its first-quarter earnings, reporting an EPS of $0.870 against an estimated $-0.040. The company's revenue also significantly topped estimates, coming in at $179.23M compared to the consensus of $400K. The stock has seen substantial growth over the past year, reflecting "good performance" according to InvestingPro.
Moderna settlement drives Arbutus (NASDAQ: ABUS) to $169.7M Q1 profit
Arbutus Biopharma reported a significant Q1 2026 profit of $169.7 million, primarily driven by a $178.7 million license revenue from its share of Genevant's settlement with Moderna. This settlement, which includes a noncontingent payment and a potential contingent payment of up to $1.3 billion, strengthens Arbutus's balance sheet with increased assets and no debt. The company also received FDA Fast Track designation for its lead chronic hepatitis B therapeutic, imdusiran, and is evaluating a return of capital to shareholders.
Arbutus Biopharma Corp 1Q 2026: Revenue $179.13M, EPS $0.87— 10-Q Summary
Arbutus Biopharma Corp reported a significant increase in first-quarter 2026 revenue to $179.13 million and diluted EPS of $0.87, driven primarily by a $178.7 million licensing settlement with Moderna. The company also highlighted pipeline progress for imdusiran, which received FDA Fast Track designation, and discussed ongoing intellectual property litigation.
Arbutus (NASDAQ: ABUS) swings to Q1 profit on $179M revenue surge
Arbutus Biopharma (NASDAQ: ABUS) reported a significant turnaround in Q1 2026, swinging to a net income of $169.7 million on $179.1 million in revenue, primarily driven by a litigation settlement with Moderna. The company expects to receive $178.7 million from a $950 million upfront payment in July 2026, part of a larger potential $2.25 billion settlement. Additionally, the FDA granted Fast Track designation to Arbutus's HBV RNAi therapeutic imdusiran, signaling potential for expedited development and review.
Arbutus: Q1 Earnings Snapshot
Arbutus Biopharma Corp. (ABUS) reported a first-quarter net income of $169.7 million, or 87 cents per share, a significant turnaround from a loss in the prior year's period. The biopharmaceutical company also posted revenues of $179.1 million. Its shares closed at $4.31, up from $3.35 a year ago.
Arbutus: Q1 Earnings Snapshot
Arbutus Biopharma Corp. reported a net income of $169.7 million for the first quarter, a significant turnaround from a loss in the same period last year. The company achieved earnings of 87 cents per share on revenues of $179.1 million. This financial performance contrasts with its share price of $4.31, up from $3.35 a year ago.
Arbutus Biopharma (ABUS): 10 Best Biotech Penny Stocks to Buy in 2026
Arbutus Biopharma (ABUS) is highlighted as one of the best biotech penny stocks for 2026, bolstered by a strong financial position with $91.5 million in cash by the end of 2025 and a narrowed net loss. Key developments include a $2.25 billion global settlement with Moderna over patent infringement, with Arbutus set to receive a significant upfront payment. The company also reported clinical success with its imdusiran program for chronic hepatitis B and recognized revenue from an LNP license with Alnylam.
5 Best Biotech Penny Stocks to Buy in 2026
This article identifies Arbutus Biopharma Corporation (NASDAQ:ABUS) as one of the best biotech penny stocks for 2026. The company recently settled a patent infringement lawsuit with Moderna for $2.25 billion, expecting a significant capital influx. This financial boost, along with progress in its clinical programs for chronic hepatitis B, positions Arbutus Biopharma favorably.
Whitefort lifts Arbutus (ABUS) economic stake to 9.8%
Whitefort Capital Master Fund and related parties have filed an amended Schedule 13D for Arbutus Biopharma Corp, reporting an 8.0% direct ownership stake, totaling 15,794,261 common shares. Additionally, Whitefort has a cash-settled total return swap with Nomura referencing 3,500,000 notional shares, increasing their total economic exposure to Arbutus to 9.8% of outstanding shares. The direct share acquisition cost approximately $41.3 million, funded from the fund's working capital.
Arbutus Biopharma (NASDAQ:ABUS) Shares Cross Above 200-Day Moving Average - Here's What Happened
Arbutus Biopharma (NASDAQ: ABUS) shares passed above their 200-day moving average of $4.43 on Thursday, closing at $4.25 on significant trading volume. The company recently exceeded quarterly earnings and revenue estimates but remains unprofitable, with a market capitalization of approximately $837 million. Analyst sentiment is mixed, holding an overall "Hold" consensus with an average target price of $5.00.
Arbutus Biopharma (ABUS) Wins FDA Fast Track for Imdusiran
Arbutus Biopharma (ABUS) has received FDA Fast Track designation for imdusiran, a treatment for chronic hepatitis B, which is expected to expedite its development and review. This news comes after a recent settlement with Moderna concerning LNP technology, valued at up to $2.25 billion, but also follows a price target reduction from Jefferies due to increased probability of Moderna prevailing in a related appeal. The company continues to develop infectious disease therapies, though the article suggests focusing on AI stocks for higher returns.
FDA grants Arbutus Biopharma drug fast track designation
The FDA has granted Fast Track designation to imdusiran, a drug developed by Warminster-based Arbutus Biopharma Corp. for chronic hepatitis B (cHBV). This designation will accelerate the development and review of the drug, which has shown potential for functional cure in clinical trials and addresses a significant unmet medical need for the millions suffering from cHBV infection worldwide.
Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability
Jefferies has lowered its price target for Arbutus Biopharma Corporation (ABUS) from $7.00 to $5.50, citing a higher probability of Moderna winning its appeal in ongoing litigation, which could affect a potential $1.3 billion payment to ABUS. This adjustment comes after Arbutus reported its Q4 2025 financial results, including a settlement with Moderna and Genevant for an upfront payment and potential additional funds tied to the appellate outcome. Arbutus, a clinical-stage biopharmaceutical company focusing on viral diseases, particularly hepatitis B, maintains a Buy rating from Jefferies despite the reduced valuation outlook.
Arbutus Biopharma (NASDAQ:ABUS) Sees Large Volume Increase - Here's Why
Arbutus Biopharma (NASDAQ:ABUS) experienced unusually strong trading volume on Wednesday, with shares last trading up about 5.2% at $4.486. Despite beating quarterly estimates for EPS and revenue, the company remains unprofitable with a negative net margin and ROE, though it continues to advance its HBV pipeline. Analysts currently maintain an average "Hold" rating for ABUS with a target price of $5.00, while institutional investors have adjusted their holdings in the biopharmaceutical company.
ABUS Receives Fast Track Designation from FDA for Imdusiran
Arbutus Biopharma Corp (ABUS) has received Fast Track designation from the FDA for its investigational drug imdusiran, intended for chronic hepatitis B. This designation aims to accelerate the development and review process for drugs addressing unmet medical needs. While the company demonstrates strong financial health, its profitability remains a challenge.
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
Arbutus Biopharma Corporation announced that the U.S. FDA has granted Fast Track designation for imdusiran, a drug for chronic hepatitis B. This designation will facilitate the development and expedited review of imdusiran, which has shown potential to achieve functional cure in trials. The company plans to work closely with the FDA to advance the drug, addressing a significant unmet medical need for the over 250 million people affected by chronic HBV worldwide.
[8-K] Arbutus Biopharma Corp Reports Material Event
Arbutus Biopharma Corp (ABUS) has reported a material event in an 8-K filing, announcing that the FDA granted Fast Track designation for imdusiran, their treatment for chronic hepatitis B. This designation aims to facilitate development and expedite the review process for investigational therapies addressing serious conditions with unmet medical needs. The company highlighted imdusiran's potential, having achieved functional cure in 10 patients to date through clinical trials.
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
Arbutus Biopharma Corporation announced that the U.S. FDA has granted Fast Track designation for imdusiran, a potential treatment for chronic hepatitis B (cHBV). This designation aims to expedite the development and review process for imdusiran, which has shown promise in clinical trials by achieving functional cure in some patients and allowing others to live medication-free. The Fast Track program could lead to earlier FDA engagement and potential for accelerated approval for the drug.
Whitefort outlines 8.1% Arbutus Biopharma (ABUS) stake in amended 13D
Whitefort Capital and its related entities have reported an 8.1% beneficial ownership in Arbutus Biopharma (ABUS), acquiring 15,794,261 common shares for approximately $41.8 million. This information was disclosed in an amended form Schedule 13D. The filing provides details on the source of funds, ownership structure, and an exhibit listing all transactions over the past 60 days.
Arbutus Biopharma (ABUS) 2026 proxy adds 16.3M-share incentive plan vote
Arbutus Biopharma is holding its 2026 Annual General and Special Meeting on May 26, 2026, where shareholders will vote on key proposals including the election of five directors, a new 2026 Omnibus Share and Incentive Plan authorizing 16.3 million common shares, an advisory vote on executive compensation, and the appointment of EY as their independent public accounting firm. The new incentive plan aims to attract and retain talent and will replace prior plans, with existing awards continuing under their original terms. The company had 196,939,679 common shares outstanding as of March 30, 2026.
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200-Day Moving Average - What's Next?
Arbutus Biopharma (NASDAQ:ABUS) recently saw its stock price cross above its 200-day moving average, reaching $4.60 before closing at $4.38. Despite beating quarterly earnings estimates, the company remains unprofitable with a negative net margin and return on equity. Analyst sentiment is mixed, with a consensus "Hold" rating and a target price of $5.00, while institutional investors hold 43.79% of the stock.
ABUS Financials: Revenue Breakdown, Margins & Competitor Comparison
Arbutus Biopharma Corp (ABUS) has a gross margin of 100%, indicating strong pricing power and manufacturing efficiency. However, its operating margin is -727.31% and net margin is -357.37%, with a Return on Equity (ROE) of -38.52%, reflecting significant unprofitability. Despite these figures, ABUS holds a substantial market capitalization of $856.19M and competes with industry leaders like CGEM and ANNX.
ABUS Should I Buy
Arbutus Biopharma Corp (ABUS) is not recommended as a strong buy for beginner, long-term investors due to a lack of clear positive momentum, absence of significant trading signals, and unimpressive financial performance. While the company boasts strong liquidity and a significant Q4 2025 revenue increase, it faces challenges with declining net income and EPS, and an ongoing patent dispute with Moderna. Analysts from Jefferies maintain a Buy rating but acknowledge the complexities of the patent case.
Arbutus: Q4 Earnings Snapshot
Arbutus Biopharma Corp. (ABUS) reported a Q4 loss of $3.8 million, or 1 cent per share, on revenue of $1.1 million. For the entire year, the company's loss narrowed to $33.5 million, with revenues reaching $14.1 million. Arbutus shares closed at $4.24, an increase from $3.28 a year prior.
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Arbutus Biopharma Corporation announced its Q4 and full-year 2025 financial results, highlighting a strong financial position with $91.5 million in cash, cash equivalents, and marketable securities. The company reported a significant settlement with Moderna for $2.25 billion regarding LNP delivery technology infringement, including a $950 million upfront payment, and noted that two additional patients in its Phase 2a clinical trials for imdusiran achieved functional cure for chronic hepatitis B. Arbutus is also evaluating a return of capital to shareholders in Q3 2026 following the Moderna settlement payment.
Arbutus Biopharma (ABUS) Q3 Loss And Revenue Drop Challenge Bullish Profitability Narratives
Arbutus Biopharma (ABUS) reported a mixed Q3 2025 with a loss of US$0.04 EPS and US$0.5 million in revenue, despite narrowing trailing twelve-month losses. The company's high P/B multiple of 11x compared to the biotech average of 2.5x is scrutinized, especially given its unprofitability. The article highlights the volatility of quarterly results and questions the sustainability of its brief Q2 profitability.
Arbutus Biopharma 2025 Financials: Reduced Annual Loss, Revenue Growth - News and Statistics
Arbutus Biopharma (ABUS) reported its financial results for Q4 and the full year 2025. The company posted a quarterly loss of $3.8 million and a full-year loss of $33.5 million, marking a reduction in its annual financial loss. Annual revenue reached $14.1 million, and the stock price was $4.24 per share, an increase from the previous year.
Arbutus: Fourth Quarter Financial Results Overview
Arbutus Biopharma Corp. reported a net loss of $3.8 million for the fourth quarter, or $0.01 per share, with revenues of $1.1 million. For the full year, the company reduced its annual loss to $33.5 million, or $0.17 per share, on total revenue of $14.1 million. The company's stock was trading at $4.24, an increase from $3.28 a year prior.
Arbutus: Fourth Quarter Financial Results Overview
Arbutus Biopharma Corp. reported a net loss of $3.8 million for the fourth quarter, or $0.01 per share, with revenues totaling $1.1 million. For the full year, the company reduced its loss to $33.5 million ($0.17 per share) and generated $14.1 million in revenue. The stock was $4.24 at the close, an increase from $3.28 the previous year.
Arbutus Biopharma (NASDAQ:ABUS) Posts Earnings Results
Arbutus Biopharma (NASDAQ:ABUS) reported better-than-expected earnings for the quarter, with EPS of ($0.01) against an estimated ($0.06) and revenue of $1.05 million against $0.83 million. Despite beating estimates, the company remains unprofitable and its shares slipped approximately 3% after the announcement. Analysts currently rate the stock as "Hold" with a consensus price target of $5.00.
Arbutus Biopharma Corp expected to post a loss of 4 cents a share - Earnings Preview
Arbutus Biopharma Corp (ABUS) is projected to report a loss of 4 cents per share. This information comes from a Refinitiv earnings preview. The article provides financial news regarding the company's expected performance.
Arbutus: Q4 Earnings Snapshot
Arbutus Biopharma Corp. (ABUS) reported a fourth-quarter loss of $3.8 million, or 1 cent per share, on revenues of $1.1 million. For the full year, the company's loss narrowed to $33.5 million, or 17 cents per share, with revenues totaling $14.1 million. The article also notes the company's stock closed at $4.24, an increase from $3.28 a year prior.
Arbutus: Q4 Earnings Snapshot
Arbutus Biopharma Corp. reported a loss of $3.8 million, or 1 cent per share, in its fourth quarter, with revenue of $1.1 million. For the full year, the company narrowed its loss to $33.5 million, or 17 cents per share, on revenue of $14.1 million. The company's shares closed at $4.24, an increase from $3.28 a year ago.
Arbutus Biopharma Hits Day Low of $4.21 Amid Price Pressure
Arbutus Biopharma Corp. experienced a significant stock decline of 8.47%, reaching an intraday low of $4.21, contrasting with the overall market. Despite this, the company has shown resilience over the past month and year, with strong institutional ownership. Its market capitalization stands at USD 821 million within the Pharmaceuticals & Biotechnology sector.
Arbutus Biopharma Corp. Experiences Revision in Stock Evaluation Amid Market Dynamics
Arbutus Biopharma Corp., a small-cap biotechnology company, has revised its stock evaluation amid current market dynamics, with its stock priced at $4.70. Despite a slight dip from its previous close, the company has delivered a 35.84% return over the past year, outperforming the S&P 500. Technical indicators show mixed signals, but the stock has demonstrated resilience, particularly with a 28.07% return last month, highlighting its ability to navigate market fluctuations.
Here's Arbutus Biopharma's share of $950M Moderna settlement
Arbutus Biopharma is set to receive $190 million from a $950 million settlement with Moderna, resolving a patent infringement lawsuit related to Moderna's Covid-19 vaccine, Spikevax. The Bucks County-based company, along with Genevant, is also involved in ongoing patent infringement lawsuits against Pfizer and BioNTech. The settlement was announced on March 3, 2026.
MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS
Moderna (MRNA) has settled a patent dispute with Genevant Sciences (a subsidiary of Roivant Sciences ROIV) and Arbutus Biopharma (ABUS) for $2.25 billion, resolving claims of unauthorized use of LNP technology in its COVID-19 and RSV vaccines. The agreement involves an upfront payment of $950 million, with a potential additional $1.3 billion if Moderna loses a federal appeal. This settlement led to Moderna's stock gaining nearly 6% in after-market trading and is expected to result in a $950 million charge in Q1 2026, though the company projects strong liquidity by year-end.
Moderna to pay about US$1 bil to settle Arbutus litigation
Moderna has agreed to pay US$950 million to settle all worldwide litigation with Arbutus Biopharma Corp and Genevant Sciences GmbH, resolving patent infringement claims related to the lipid nanoparticle technology used in its Covid-19 vaccine. This settlement removes a significant financial risk for Moderna, which had struggled to launch new products after the initial success of its vaccine. While Moderna's shares rose, Arbutus's fell, indicating investor disappointment regarding potential future payouts.
Moderna to pay Genevant Sciences and Arbutus Biopharma up to $2.25 billion in global patent settlement
Moderna has agreed to a global settlement with Genevant Sciences and Arbutus Biopharma, totaling up to $2.25 billion, to resolve patent infringement claims related to its COVID-19 vaccine, Spikevax. The dispute concerned Moderna's unauthorized use of Genevant's and Arbutus' LNP delivery technology. The settlement includes an upfront payment of $950 million in July 2026 and an additional $1.3 billion contingent on an appellate ruling regarding a specific legal statute.
Arbutus Biopharma Reaches Transformative Global Settlement With Moderna
Arbutus Biopharma and Genevant Sciences have reached a $2.25 billion global settlement with Moderna to resolve all LNP patent disputes related to Moderna's COVID-19 vaccines, including Spikevax. Moderna will make an upfront payment of $950 million and potentially an additional $1.3 billion, securing a non-exclusive license for SM-102 LNP vaccine technology. This agreement is described as transformative for Arbutus, which is considering a return of capital to shareholders, while separate litigation against Pfizer/BioNTech continues.
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Settlement with Moderna Over LNP Technology Patent Infringement
Genevant Sciences and Arbutus Biopharma have reached a $2.25 billion settlement with Moderna regarding patent infringement over the unauthorized use of Genevant's lipid nanoparticle (LNP) delivery technology in Moderna's COVID-19 vaccines. The settlement includes an upfront payment of $950 million and a contingent payment of $1.3 billion, pending the outcome of Moderna's appeal concerning Section 1498. This agreement grants Moderna a global non-exclusive license for the LNP technology for infectious disease applications and resolves all related litigation, while similar litigation against Pfizer/BioNTech is still ongoing.
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Settlement with Moderna Over LNP Technology Patent Infringement
Genevant Sciences and Arbutus Biopharma have reached a $2.25 billion settlement with Moderna regarding patent infringement over the unauthorized use of Genevant's LNP delivery technology in Moderna's COVID-19 vaccines. The settlement includes an upfront payment of $950 million due in July 2026 and an additional contingent payment of $1.3 billion depending on the outcome of Moderna's appeal concerning Section 1498. This agreement, which establishes the validity of Genevant/Arbutus patents and grants Moderna a non-exclusive license, resolves all related U.S. and international litigation.
Arbutus Biopharma (Nasdaq: ABUS) details $2.25B Moderna patent settlement
Arbutus Biopharma and Genevant Sciences have reached a global patent settlement with Moderna for up to $2.25 billion, resolving all litigation related to lipid nanoparticle (LNP) technology. The settlement includes an upfront payment of $950 million by July 2026 and a contingent payment of $1.3 billion based on the outcome of Moderna’s Section 1498 appeal. Arbutus is entitled to 20% of the settlement proceeds after litigation costs and is evaluating a potential return of capital to shareholders.
$2.25 billion Moderna deal ends COVID vaccine patent fight
Arbutus Biopharma and Genevant Sciences announced a $2.25 billion global settlement with Moderna over the unauthorized use of their LNP delivery technology in COVID-19 vaccines. The settlement includes an upfront payment of $950 million in July 2026 and a contingent $1.3 billion payment tied to an appellate ruling on Section 1498. As part of the agreement, Moderna receives a global non-exclusive license to the LNP technology for infectious disease applications, effectively ending the patent infringement litigation against Moderna.
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
Genevant Sciences and Arbutus Biopharma have reached a $2.25 billion global settlement with Moderna over the unauthorized use of their LNP delivery technology in Moderna's COVID-19 vaccines. The settlement includes an upfront payment of $950 million and a contingent payment of $1.3 billion. Arbutus Biopharma is evaluating a return of capital to shareholders in Q3 2026, and Roivant will host an investor call to discuss the updates.
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
Genevant Sciences and Arbutus Biopharma have reached a $2.25 billion global settlement with Moderna over the unauthorized use of their LNP delivery technology in Moderna's COVID-19 vaccines. The settlement includes an upfront payment of $950 million and a contingent payment of an additional $1.3 billion, pending a favorable appellate ruling on Moderna's Section 1498 defense. This agreement resolves all patent-infringement litigation against Moderna, while litigation against Pfizer/BioNTech is ongoing. Arbutus Biopharma is also evaluating a return of capital to shareholders.
